安科生物：公司的曲妥珠单抗“安赛汀”2023年底获批上市

Core Viewpoint - Anke Bio's trastuzumab product "Ansaiting" is expected to be approved for market launch by the end of 2023, with projected revenue of 100 million yuan in 2024, and significant year-on-year growth in revenue for the first nine months of 2025, although current profits from this product are relatively low [1] Group 1 - The company anticipates that the upcoming centralized procurement of biosimilars will be beneficial for manufacturers entering the market later, as the current procurement policies are relatively mild [1] - After several rounds of price reductions, the price impact on the market is expected to be minimal, allowing the company to quickly transform this product from a revenue-generating product to a profit-generating product by rapidly reducing sales expenses [1]